Detalles de la búsqueda
1.
Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study.
Invest New Drugs
; 41(2): 306-316, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36892745
2.
Economic Analysis of Exclusionary EGFR Test Versus Up-Front NGS for Lung Adenocarcinoma in High EGFR Mutation Prevalence Areas.
J Natl Compr Canc Netw
; 20(7): 774-782.e4, 2022 04 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35385830
3.
Dynamic Assessment of Tissue and Plasma EGFR-Activating and T790M Mutations with Droplet Digital PCR Assays for Monitoring Response and Resistance in Non-Small Cell Lung Cancers Treated with EGFR-TKIs.
Int J Mol Sci
; 23(19)2022 Sep 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-36232650
4.
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Lancet Oncol
; 21(2): 261-270, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31838015
5.
Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY.
Cancer Sci
; 111(12): 4510-4525, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32954593
6.
An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas.
Oncologist
; 25(5): e782-e788, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31852810
7.
Functional outcomes and survival after surgical stabilization for inoperable non-small-cell lung cancer with spinal metastasis of the thoracic and lumbar spines: a retrospective comparison between epidermal growth factor receptor-tyrosine kinase inhibitor and platinum-based chemotherapy groups.
Spinal Cord
; 58(2): 194-202, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31501501
8.
Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan.
J Formos Med Assoc
; 119(12): 1817-1826, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32094063
9.
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 20(12): 1655-1669, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31591063
10.
Pneumatosis intestinalis induced by targeted therapy.
Postgrad Med J
; 98(1155): 10, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33234706
11.
Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation.
J Formos Med Assoc
; 119(9): 1439-1441, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32173232
12.
Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study.
Lung Cancer
; 190: 107530, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38471416
13.
Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer.
Lung Cancer
; 188: 107442, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38171156
14.
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.
J Clin Oncol
; 42(3): 324-335, 2024 Jan 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37976444
15.
Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722.
J Clin Oncol
; 42(11): 1252-1264, 2024 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38252907
16.
Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study.
Lancet Respir Med
; 12(2): 141-152, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38042167
17.
Hypoxia inhibits senescence and maintains mesenchymal stem cell properties through down-regulation of E2A-p21 by HIF-TWIST.
Blood
; 117(2): 459-69, 2011 Jan 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-20952688
18.
Prognosticators of osimertinib treatment outcomes in patients with EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis.
J Cancer Res Clin Oncol
; 149(1): 5-14, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36318332
19.
Efficacy of different platforms in detecting EGFR mutations using cerebrospinal fluid cell-free DNA from non-small-cell lung cancer patients with leptomeningeal metastases.
Thorac Cancer
; 14(14): 1251-1259, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36977550
20.
Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study.
Target Oncol
; 18(4): 505-515, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37329423